Decreased Circulating Sclerostin Levels in Renal Transplant Recipients With Persistent Hyperparathyroidism
- 1 October 2016
- journal article
- research article
- Published by Wolters Kluwer Health in Transplantation
- Vol. 100 (10) , 2188-2193
Abstract
Background Sclerostin is an osteocyte-secreted soluble antagonist of the Wnt/β-catenin signaling pathway requisite for osteoblast development and activity. The regulation of sclerostin expression in bone is complex. Parathyroid hormone (PTH) is recognized to be an important suppressor. Circulating sclerostin levels are 2- to 4-fold higher in patients with end-stage renal disease as compared with individuals with normal renal function. Methods We performed a longitudinal observational cohort study and case-control study in 50 de novo renal transplant recipients, 50 chronic kidney disease (CKD) patients (n = 50) matched for age, sex, and estimated glomerular filtration rate, and 23 renal transplant recipients referred for parathyroidectomy to define the impact of renal transplantation on circulating sclerostin levels and to clarify the role of persistent (tertiary) hyperparathyroidism. Results Sclerostin serum levels decreased by 61.2% (median) during the first 3 months after transplantation (1.24 vs 0.44 ng/mL, P < 0.0001) to increase thereafter toward levels observed in CKD counterparts (0.63 ng/ml). High PTH levels independently associated with low sclerostin levels, both at time of transplantation and at 1 year. Sclerostin levels significantly increased after parathyroidectomy (0.49 vs. 0.32 ng/ml, P < 0.0001). The time course of bone biomarkers after parathyroidectomy suggests that bone resorption normalizes earlier than bone formation. Conclusions Circulating sclerostin levels appear to show a biphasic pattern after renal transplantation with a rapid and profound decrease, followed by gradual increase towards levels observed in CKD counterparts. Our data support the notion that PTH is an important regulator of circulating sclerostin levels.Keywords
This publication has 28 references indexed in Scilit:
- Sclerostin and Dickkopf-1 in Post-menopausal Renal Allograft RecipientsTransplantation Proceedings, 2014
- Renal Elimination of Sclerostin Increases With Declining Kidney FunctionThe Journal of Clinical Endocrinology & Metabolism, 2014
- TNF‐α Upregulates Sclerostin Expression in Obese Mice Fed a High‐Fat DietJournal of Cellular Physiology, 2013
- The Relation between Renal Function and Serum Sclerostin in Adult Patients with CKDClinical Journal of the American Society of Nephrology, 2013
- WNT signaling in bone homeostasis and disease: from human mutations to treatmentsNature Medicine, 2013
- Repression of osteocyte Wnt/β-catenin signaling is an early event in the progression of renal osteodystrophyJournal of Bone and Mineral Research, 2012
- Sclerostin and Its Association with Physical Activity, Age, Gender, Body Composition, and Bone Mineral Content in Healthy AdultsThe Journal of Clinical Endocrinology & Metabolism, 2012
- Calcitonin impairs the anabolic effect of PTH in young rats and stimulates expression of sclerostin by osteocytesBone, 2010
- Parathyroid hormone (PTH)–induced bone gain is blunted in SOST overexpressing and deficient miceJournal of Bone and Mineral Research, 2010
- Mechanical Stimulation of Bone in Vivo Reduces Osteocyte Expression of Sost/SclerostinJournal of Biological Chemistry, 2008